1. 188PDImpact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC). (23rd October 2018) Authors: Untch, M; Jackisch, C; Schneeweiss, A; Schmatloch, S; Aktas, B; Denkert, C; Schem, C; Wiebringhaus, H; Kümmel, S; Rhiem, K; Warm, M; Fasching, P A; Just, M; Hanusch, C; Hackmann, J; Blohmer, J-U; Furlanetto, J; Nekljudova, V; von Minckwitz, G; Loibl, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LBA13Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplatin or gemcitabine: Survival results of WSG-ADAPT-TN phase II trial. (23rd October 2018) Authors: Gluz, O; Nitz, U; Liedtke, C; Christgen, M; Grischke, E-M; Forstbauer, H; Braun, M; Warm, M; Hackmann, J; Uleer, C; Aktas, B; Schumacher, C; Lindner, C; Kümmel, S; Kates, R E; Potenberg, J; Staib, P; Wuerstlein, R; Kreipe, H H; Harbeck, N Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗